HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.
HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.